V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220018106 | 220009457 | 1.49 | 54.9 | Curative (C) | 2013-12-25 | 2014-04-21 | Capecitabine | N | N | 220035858 | EC |
| 220018107 | 220009461 | 0 | 87.1 | Curative (C) | 2015-08-18 | 2015-10-02 | CHOP R - 14 days | N | N | 220035874 | MERCAPTOPURINE |
| 220018108 | 220009464 | null | null | Curative (C) | 2015-04-04 | 2015-06-01 | Alemtuzumab + Cyclophos TBI Allo | 2 | N | 220035882 | MYELOMA XI TRIAL |
| 220018110 | 220015023 | 1.64 | null | Curative (C) | 2014-12-12 | 2014-12-12 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | N | N | 220035925 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220018111 | 220009472 | 1.8 | 60 | null | 2013-08-05 | 2013-08-20 | Irinotecan 14day | 2 | N | 220035943 | INTERFERON |
| 220018112 | 220009474 | 1.58 | 67 | Palliative (P) | 2016-11-05 | 2016-11-09 | MidAC | N | N | 220035947 | UKALL 60+ TRIAL |
| 220018113 | 220018199 | 1.7 | null | Palliative (P) | 2017-01-21 | 2017-02-04 | Arsenic trioxide | N | null | 220035957 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018114 | 220009480 | 1.75 | 48 | Palliative (P) | null | 2017-08-17 | Carboplatin + Liposomal Doxorubicin | N | N | 220035959 | CYTARABINE + FLUDARABINE |
| 220018115 | 220009481 | 1.5 | 35.1 | Palliative (P) | 2017-04-12 | 2017-04-12 | BENDAMUSTINE + RITUXIMAB | null | N | 220035962 | MELPHALAN |
| 220018116 | 220009482 | null | 65.2 | Curative (C) | 2017-04-05 | 2017-04-05 | Sorafenib | N | N | 220035963 | CARBOPLATIN |
| 220018117 | 220015031 | 1.75 | 76 | Palliative (P) | 2016-01-14 | 2016-09-03 | CETUXIMAB | N | N | 220035969 | FIGARO TRIAL |
| 220018118 | 220009485 | null | null | Palliative (P) | 2015-04-29 | 2015-04-29 | MYELOMA XI TRIAL | N | N | 220035980 | MYELOMA XI TRIAL |
| 220018119 | 220009486 | 1.68 | 96.7 | Palliative (P) | 2015-12-30 | 2016-01-07 | Arsenic Trioxide (Induction Week) | N | N | 220036003 | LIPOSOMAL DOXORUBICIN |
| 220018120 | 220009488 | 1.64 | 65.6 | Curative (C) | 2015-01-25 | 2016-01-06 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | N | null | 220036006 | VINORELBINE |
| 220018121 | 220009489 | 1.45 | 44.4 | Curative (C) | 2013-12-29 | 2014-04-08 | MACE | 01 | N | 220036013 | UKALL60+ |
| 220018122 | 220021600 | 1.83 | null | Curative (C) | null | 2015-10-12 | FLUDARABINE | null | null | 220036020 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018123 | 220009491 | 1.76 | 112 | Palliative (P) | 2014-09-17 | 2014-10-21 | Cisplatin 7 day | N | N | 220036034 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 220018124 | 220015037 | 1.69 | 75 | Not known (9) | 2014-01-20 | 2014-01-23 | Spanish Maintenance (Months 1-3) | null | N | 220036041 | METHOTREXATE + PEGASPARGASE |
| 220018125 | 220009495 | 1.8 | 99 | Curative (C) | 2016-10-17 | 2016-10-24 | IPILIMUMAB + NIVOLUMAB | 02 | N | 220036053 | LI-1 TRIAL |
| 220018126 | 220009497 | 1.65 | 38.8 | Disease modification (D) | 2016-11-10 | 2016-11-11 | Cladribine (subcut) 5 days | N | N | 220036057 | TOPOTECAN |
| 220018127 | 220009500 | 1.5 | 0 | Curative (C) | 2015-04-13 | 2015-05-03 | FIGARO TRIAL | 02 | N | 220036062 | LENALIDOMIDE |
| 220018128 | 220009502 | null | null | Curative (C) | 2016-05-28 | 2016-05-30 | CETUXIMAB | null | N | 220036081 | VINCRISTINE |
| 220018129 | 220009506 | null | null | Curative (C) | 2014-04-19 | 2014-04-19 | GEMCITABINE | N | null | 220036098 | MITOXANTRONE + TRETINOIN |
| 220018131 | 220009509 | null | null | Palliative (P) | 2015-09-05 | 2015-09-05 | CLOFARABINE + DAUNORUBICIN | 99 | null | 220036121 | CYTARABINE + FLUDARABINE |
| 220018133 | 220009519 | 1.51 | 47.4 | null | 2015-12-07 | 2017-05-22 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | 220036150 | GEMCITABINE |
| 220018134 | 220015050 | 1.6 | 105 | Disease modification (D) | 2017-03-02 | 2017-12-22 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | 220036180 | BUSULPHAN |
| 220018135 | 220019991 | 1.58 | 58 | Curative (C) | 2017-05-28 | 2017-06-10 | Gemcitabine + Paclitaxel | N | N | 220036184 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220018136 | 220022120 | 1.91 | 166.7 | Curative (C) | 2016-10-14 | 2017-02-04 | Trastuzumab Subcutaneous | 2 | N | 220036189 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018137 | 220015051 | 1.69 | null | Curative (C) | 2018-06-25 | 2018-07-26 | FEC 60 or 75 | 02 | N | 220036201 | EOX |
| 220018138 | 220009525 | 1.67 | 48.8 | Palliative (P) | 2015-11-05 | 2015-11-06 | Cytarabine + Idarubicin | N | N | 220036202 | DABRAFENIB + TRAMETINIB |
| 220018139 | 220009529 | null | null | Curative (C) | 2014-08-04 | 2014-09-03 | Capecitabine + Oxaliplatin 21day | N | null | 220036215 | CARBOPLATIN |
| 220018140 | 220009532 | null | 48.6 | Curative (C) | 2015-11-29 | 2016-01-28 | MITOXANTRONE + TRETINOIN | 02 | N | 220036225 | CLADRIBINE |
| 220018141 | 220009533 | 1.72 | 77 | Disease modification (D) | 2017-10-29 | 2017-10-29 | FIGARO TRIAL | N | N | 220036225 | BUSULFAN + FLUDARABINE + METHOTREXATE |
| 220018142 | 220009536 | 1.81 | 87.1 | Palliative (P) | 2015-02-25 | 2015-02-26 | DAUNORUBICIN | N | N | 220036230 | POMALIDOMIDE |
| 220018144 | 220015059 | 1.81 | 76.1 | Palliative (P) | 2016-12-29 | 2017-03-29 | Capecitabine | 02 | N | 220036240 | PACKER INDUCTION VINCRISTINE + RT |
| 220018145 | 220015060 | null | null | Curative (C) | 2015-06-04 | 2015-06-14 | Ipilimumab | Y | N | 220036241 | MELPHALAN |
| 220018146 | 220009541 | null | null | Palliative (P) | 2018-11-23 | 2018-11-23 | Cyclophosphamide+Etopophos HD | N | null | 220036245 | BEAM |
| 220018147 | 220019994 | 1.8 | 73 | Palliative (P) | 2016-01-26 | 2016-01-26 | Mercaptopurine | 02 | N | 220036278 | CAV |
| 220018148 | 220019994 | 1.3 | null | Curative (C) | 2016-12-13 | 2017-07-27 | Erlotinib | N | null | 220036278 | BORTEZOMIB |
| 220018150 | 220009545 | 1.96 | 79.9 | Palliative (P) | 2016-01-05 | 2016-01-11 | Cyclophosphamide High Dose | 02 | N | 220036286 | CYTARABINE + METHOTREXATE |
| 220018151 | 220009546 | 1.72 | 103 | null | 2012-02-07 | 2015-05-17 | ALL UKALL2011 TRIAL | N | N | 220036297 | PEMBROLIZUMAB |
| 220018152 | 220009550 | null | 93.6 | Curative (C) | 2016-03-26 | 2017-04-19 | Methotrexate High Dose (3g/m2) | 02 | null | 220036312 | MELPHALAN |
| 220018154 | 220009555 | 1.59 | null | Curative (C) | 2014-04-14 | 2014-04-19 | Cisplatin | Y | null | 220036331 | BUSULFAN + FLUDARABINE |
| 220018155 | 220009557 | 0 | 68 | Curative (C) | 2017-05-03 | 2017-05-07 | Capecitabine + Oxaliplatin 21day | 02 | Y | 220036334 | NIVOLUMAB |
| 220018156 | 220009559 | null | 57 | Curative (C) | 2016-04-17 | 2016-07-08 | MidAC | 2 | N | 220036338 | CETUXIMAB + IRINOTECAN + MDG |
| 220018157 | 220009564 | 1.66 | 7.1 | Curative (C) | 2018-12-28 | 2018-12-28 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 220036370 | CAPECITABINE + OXALIPLATIN |
| 220018158 | 220009566 | null | null | Palliative (P) | 2014-03-03 | 2014-03-07 | FLUDARABINE | N | null | 220036395 | GEMCITABINE |
| 220018159 | 220009568 | 1.8 | 71.8 | Curative (C) | 2017-12-05 | 2018-02-27 | BUSULFAN + CYCLOPHOSPHAMIDE | N | N | 220036408 | CAPECITABINE + OXALIPLATIN |
| 220018160 | 220009570 | 1.65 | null | Disease modification (D) | 2016-12-19 | 2017-05-13 | Bortezomib + Cyclophos + Dex | null | null | 220036412 | FLA |
| 220018161 | 220009572 | 1.78 | 83.3 | Curative (C) | 2013-07-02 | 2017-01-01 | CARBOPLATIN + VINORELBINE | N | N | 220036413 | CAPECITABINE + OXALIPLATIN |